Last reviewed · How we verify
Azithromycin to infants
At a glance
| Generic name | Azithromycin to infants |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (PHASE4)
- Vitality in Infants Via Azithromycin for Neonates Trial (PHASE4)
- THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA (PHASE4)
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol] (NA)
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali (PHASE3)
- Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth (PHASE3)
- Infant Mortality Reduction by the Mass Administration of Azithromycin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin to infants CI brief — competitive landscape report
- Azithromycin to infants updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI